{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T15:35:23Z","timestamp":1793115323153,"version":"4.5.0"},"reference-count":41,"publisher":"American Society of Hematology","issue":"20","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,10,27]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>There is no established standard treatment of relapsed\/refractory (R\/R) marginal zone lymphoma (MZL). Zanubrutinib was approved in this setting based on the phase 2 MAGNOLIA trial. We retrospectively evaluated the characteristics and outcomes of 118 real-world patients in Spain with R\/R MZL treated with zanubrutinib after at least 1 previous anti-CD20\u2013based regimen. The median age at zanubrutinib initiation was 75 years, and 56% were female. MZL subtypes included splenic (55.3%), mucosa-associated lymphoid tissue (18.9%), nodal (19.8%), and nonclassifiable (6%). The median number of previous lines of therapy (LoT) was 1.5 (range, 1-7); 26% of patients had MZL refractory to the immediately preceding line, and 59% experienced progression of disease within 24 months (POD24) to frontline therapy. In total, 31 patients (26.3%) would not have met MAGNOLIA trial eligibility criteria, 68% had cardiovascular comorbidities, and 28% were receiving antithrombotic therapy. The overall and complete response rates were 76% and 22.2%, respectively, with no differences according to MZL subtype, age, POD24, or MAGNOLIA trial eligibility. Fewer previous LoT were associated with higher and deeper responses. With a median follow-up of 14 months, 1-year progression-free and overall survival were 79.4% and 86.8%, respectively. Zanubrutinib responders and patients with stable disease presented better outcomes than those with progressing disease (P&amp;lt; .01). Adverse events (AEs) were reported in 34.1% of patients (grade \u22653 in 14.4%). MAGNOLIA trial\u2013ineligible patients experienced a higher incidence of AEs, and bleeding events were more frequent among patients receiving anticoagulant therapy (P = .04). Overall, zanubrutinib demonstrated favorable effectiveness and safety in real-world R\/R MZL, with improved outcomes when administered earlier in the disease.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2026020480","type":"journal-article","created":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T21:00:32Z","timestamp":1787691632000},"page":"7036-7047","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":0,"title":["Real-world effectiveness and safety of zanubrutinib in Spanish patients with relapsed\/refractory marginal zone lymphoma"],"prefix":"10.1182","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2714-6731","authenticated-orcid":false,"given":"Fernando","family":"Martin-Moro","sequence":"first","affiliation":[{"name":"1Department of Hematology, Ram\u00f3n y Cajal University Hospital\/Ram\u00f3n y Cajal Health Research Institute, Doctoral Program in Health Sciences, University of Alcala, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7839-6648","authenticated-orcid":false,"given":"Ana","family":"Munta\u00f1ola","sequence":"additional","affiliation":[{"name":"2Department of Hematology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2622-5430","authenticated-orcid":false,"given":"Xabier","family":"Guti\u00e9rrez","sequence":"additional","affiliation":[{"name":"3Department of Hematology, Hospital Universitario de \u00c1lava, Vitoria, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6374-0223","authenticated-orcid":false,"given":"Mar\u00eda Sof\u00eda","family":"V\u00e1zquez","sequence":"additional","affiliation":[{"name":"4Department of Hematology, Hospital Universitario Juan Ram\u00f3n Jim\u00e9nez, Huelva, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luc\u00eda","family":"Morais","sequence":"additional","affiliation":[{"name":"5Department of Hematology, Hospital Universitario Central de Asturias, Oviedo, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Itxaso","family":"Amarika","sequence":"additional","affiliation":[{"name":"6Department of Hematology, Hospital Universitario Galdakao-Usansolo, Bilbao, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ram\u00f3n","family":"Diez-Feij\u00f3o","sequence":"additional","affiliation":[{"name":"7Department of Hematology, Hospital del Mar, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariana","family":"Bastos-Oreiro","sequence":"additional","affiliation":[{"name":"8Department of Hematology, Hospital Universitario Gregorio Mara\u00f1\u00f3n, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3223-0121","authenticated-orcid":false,"given":"Beatriz de la","family":"Cruz","sequence":"additional","affiliation":[{"name":"9Department of Hematology, Hospital Universitario La Paz, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7518-229X","authenticated-orcid":false,"given":"Javier","family":"Marco-Ayala","sequence":"additional","affiliation":[{"name":"10Department of Hematology, Hospital Morales Meseguer, Murcia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1770-7614","authenticated-orcid":false,"given":"Sergio","family":"Ramos","sequence":"additional","affiliation":[{"name":"11Department of Hematology, Hospital Fundaci\u00f3n Jim\u00e9nez D\u00edaz, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Jim\u00e9nez-Ubieto","sequence":"additional","affiliation":[{"name":"12Department of Hematology, Hospital Universitario 12 de Octubre, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-6286-5586","authenticated-orcid":false,"given":"Pablo","family":"Galindo-Navarro","sequence":"additional","affiliation":[{"name":"13Department of Hematology, Hospital Universitario Virgen de las Nieves, Granada, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Gonzalo","family":"Correa","sequence":"additional","affiliation":[{"name":"14Department of Hematology, Hospital Cl\u00ednic Barcelona, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1490-0678","authenticated-orcid":false,"given":"Esperanza","family":"Lavilla","sequence":"additional","affiliation":[{"name":"15Department of Hematology, Hospital Universitario Lucus Augusti, Lugo, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4180-4713","authenticated-orcid":false,"given":"Cristina","family":"Garc\u00eda-Herce","sequence":"additional","affiliation":[{"name":"16Department of Hematology, Hospital Universitari Vall d\u2019Hebron, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-8711-5746","authenticated-orcid":false,"given":"Miriam","family":"Moreno","sequence":"additional","affiliation":[{"name":"17Department of Hematology, Institut Catal\u00e0 d\u2019Oncologia Germans Trias i Pujol, Badalona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8907-090X","authenticated-orcid":false,"given":"Eva","family":"Domingo-Dom\u00e9nech","sequence":"additional","affiliation":[{"name":"18Department of Hematology, Institut Catal\u00e0 d\u2019Oncologia Duran i Reynals, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-8545-5367","authenticated-orcid":false,"given":"Nazaret","family":"Dom\u00ednguez","sequence":"additional","affiliation":[{"name":"19Department of Hematology, Hospital Virgen de la Macarena, Seville, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ar\u00e1nzazu","family":"Alonso","sequence":"additional","affiliation":[{"name":"20Department of Hematology, Hospital Ruber Juan Bravo, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Jos\u00e9","family":"Otero","sequence":"additional","affiliation":[{"name":"21Department of Hematology, Hospital G\u00f3mez Ulla, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Comai","sequence":"additional","affiliation":[{"name":"22Department of Hematology, Hospital Mois\u00e9s Broggi, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Luisa","family":"Bengochea","sequence":"additional","affiliation":[{"name":"23Department of Hematology, Hospital Universitario Severo Ochoa, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5340-3570","authenticated-orcid":false,"given":"Carolina","family":"Villegas Da Ros","sequence":"additional","affiliation":[{"name":"24Department of Hematology, Hospital Universitario Arnau de Vilanova, Valencia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5834-9510","authenticated-orcid":false,"given":"Norma C.","family":"Guti\u00e9rrez","sequence":"additional","affiliation":[{"name":"25Department of Hematology, Hospital Universitario de Salamanca, Instituto de Investigaci\u00f3n Biom\u00e9dica de Salamanca, Salamanca, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1358-5186","authenticated-orcid":false,"given":"Rafael","family":"Lluch","sequence":"additional","affiliation":[{"name":"26Department of Hematology, Hospital de Manises, Valencia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9630-5893","authenticated-orcid":false,"given":"Sara","family":"Fern\u00e1ndez-Luis","sequence":"additional","affiliation":[{"name":"27Department of Hematology, Hospital Universitario Marqu\u00e9s de Valdecilla, Santander, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4304-8472","authenticated-orcid":false,"given":"Joan-Alfons","family":"Soler","sequence":"additional","affiliation":[{"name":"28Department of Hematology, Hospital Universitari Parc Taul\u00ed, Sabadell, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8971-2279","authenticated-orcid":false,"given":"M. Jimena","family":"Cannata-Ortiz","sequence":"additional","affiliation":[{"name":"29Department of Hematology, Hospital Universitario La Princesa, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c1ngeles","family":"Medina","sequence":"additional","affiliation":[{"name":"30Department of Hematology, Hospital Universitario Costa del Sol, Marbella, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sof\u00eda","family":"Mart\u00edn-Consuegra","sequence":"additional","affiliation":[{"name":"31Department of Hematology, Hospital Comarcal de Alca\u00f1iz, Teruel, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Aceituno","sequence":"additional","affiliation":[{"name":"32Department of Hematology, Hospital Universitario de Ferrol, A Coru\u00f1a, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8580-5382","authenticated-orcid":false,"given":"Paola","family":"Villafuerte","sequence":"additional","affiliation":[{"name":"33Department of Hematology, Hospital Universitario Pr\u00edncipe de Asturias, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dunia","family":"de Miguel","sequence":"additional","affiliation":[{"name":"34Department of Hematology, Hospital Universitario de Guadalajara, Guadalajara, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Mar\u00eda","family":"Argui\u00f1ano","sequence":"additional","affiliation":[{"name":"35Department of Hematology, Hospital Universitario de Navarra, Pamplona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"L\u00f3pez","sequence":"additional","affiliation":[{"name":"36Department of Hematology, Hospital Universitario Doctor Balmis, Alicante, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luc\u00eda","family":"Villal\u00f3n","sequence":"additional","affiliation":[{"name":"37Department of Hematology, Hospital Universitario Fundaci\u00f3n Alcorc\u00f3n, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Horacio","family":"Gulino","sequence":"additional","affiliation":[{"name":"38Department of Hematology, Hospital Universitario Nuestra Se\u00f1ora del Prado, Toledo, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armando","family":"L\u00f3pez-Guillermo","sequence":"additional","affiliation":[{"name":"14Department of Hematology, Hospital Cl\u00ednic Barcelona, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Salar","sequence":"additional","affiliation":[{"name":"39Department of Hematology, Hospital Universitario Virgen de la Arrixaca, Murcia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2026,10,16]]},"reference":[{"issue":"4","key":"2026102711120399900_bib1","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1007\/s00277-020-03918-6","article-title":"RELINF: prospective epidemiological registry of lymphoid neoplasms in Spain. A project from the GELTAMO group","volume":"99","author":"Bastos-Oreiro","year":"2020","journal-title":"Ann Hematol"},{"key":"2026102711120399900_bib2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.21037\/aol-20-28","article-title":"Epidemiology of marginal zone lymphoma","volume":"5","author":"Cerhan","year":"2021","journal-title":"Ann Lymphoma"},{"issue":"6","key":"2026102711120399900_bib3","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1056\/NEJMra2102568","article-title":"Marginal-zone lymphomas","volume":"386","author":"Rossi","year":"2022","journal-title":"N Engl J Med"},{"issue":"7","key":"2026102711120399900_bib4","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","article-title":"The 5th edition of the World Health Organization classification of haematolymphoid tumours: lymphoid neoplasms","volume":"36","author":"Alaggio","year":"2022","journal-title":"Leukemia"},{"issue":"11","key":"2026102711120399900_bib5","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1182\/blood.2022015851","article-title":"The International Consensus Classification of mature lymphoid neoplasms: a report from the Clinical Advisory Committee","volume":"140","author":"Campo","year":"2022","journal-title":"Blood"},{"issue":"4","key":"2026102711120399900_bib6","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1111\/bjh.18912","article-title":"Low-risk HPLLs\/ABC score patients with splenic marginal zone lymphoma can be safely managed without treatment: results from a prospective Spanish study","volume":"202","author":"Munta\u00f1ola","year":"2023","journal-title":"Br J Haematol"},{"issue":"2","key":"2026102711120399900_bib7","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1182\/blood.2024028269","article-title":"The treatment of marginal zone lymphoma","volume":"147","author":"Alderuccio","year":"2026","journal-title":"Blood"},{"key":"2026102711120399900_bib8","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1111\/bjh.19064","article-title":"Guideline for the diagnosis and management of marginal zone lymphomas: a British Society of Haematology guideline","volume":"204","author":"Walewska","year":"2024","journal-title":"Br J Haematol"},{"issue":"1","key":"2026102711120399900_bib9","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.annonc.2019.10.010","article-title":"Marginal zone lymphomas: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"31","author":"Zucca","year":"2020","journal-title":"Ann Oncol"},{"issue":"15","key":"2026102711120399900_bib10","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1182\/blood-2017-07-795302","article-title":"Long-term results of a phase 2 study of rituximab and bendamustine for mucosa-associated lymphoid tissue lymphoma","volume":"130","author":"Salar","year":"2017","journal-title":"Blood"},{"issue":"14","key":"2026102711120399900_bib11","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1200\/JCO.19.00010","article-title":"AUGMENT: a phase III study of lenalidomide plus rituximab versus placebo plus rituximab in relapsed or refractory indolent lymphoma","volume":"37","author":"Leonard","year":"2019","journal-title":"J Clin Oncol"},{"issue":"2","key":"2026102711120399900_bib12","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1182\/blood.2024028268","article-title":"The biology of marginal zone lymphoma subtypes: challenge and relevance of classification","volume":"147","author":"Laurent","year":"2026","journal-title":"Blood"},{"issue":"1","key":"2026102711120399900_bib13","doi-asserted-by":"crossref","first-page":"176","DOI":"10.3390\/cancers14010176","article-title":"Recent advances in the genetic of MALT lymphomas","volume":"14","author":"Rodr\u00edguez-Sevilla","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"17","key":"2026102711120399900_bib14","doi-asserted-by":"crossref","first-page":"2072","DOI":"10.1182\/blood-2015-11-624312","article-title":"Splenic marginal zone lymphoma: from genetics to management","volume":"127","author":"Arcaini","year":"2016","journal-title":"Blood"},{"issue":"8","key":"2026102711120399900_bib15","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1056\/NEJMoa2409804","article-title":"Fixed-duration acalabrutinib combinations in untreated chronic lymphocytic leukemia","volume":"392","author":"Brown","year":"2025","journal-title":"N Engl J Med"},{"issue":"10514","key":"2026102711120399900_bib16","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1016\/S0140-6736(25)01432-1","article-title":"Ibrutinib and rituximab versus immunochemotherapy in patients with previously untreated mantle cell lymphoma (ENRICH): a randomised, open-label, phase 2\/3 superiority trial","volume":"406","author":"Lewis","year":"2025","journal-title":"Lancet"},{"issue":"20","key":"2026102711120399900_bib17","doi-asserted-by":"crossref","first-page":"2276","DOI":"10.1200\/JCO-25-00690","article-title":"Acalabrutinib plus bendamustine-rituximab in untreated mantle cell lymphoma","volume":"43","author":"Wang","year":"2025","journal-title":"J Clin Oncol"},{"issue":"3","key":"2026102711120399900_bib18","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1038\/nrd3937","article-title":"Targeting pathological B cell receptor signalling in lymphoid malignancies","volume":"12","author":"Young","year":"2013","journal-title":"Nat Rev Drug Discov"},{"issue":"25","key":"2026102711120399900_bib19","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1056\/NEJMoa1802917","article-title":"Phase 3 trial of ibrutinib plus rituximab in Waldenstr\u00f6m\u2019s macroglobulinemia","volume":"378","author":"Dimopoulos","year":"2018","journal-title":"N Engl J Med"},{"issue":"16","key":"2026102711120399900_bib20","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1182\/blood-2016-10-747345","article-title":"Targeting Bruton tyrosine kinase with ibrutinib in relapsed\/refractory marginal zone lymphoma","volume":"129","author":"Noy","year":"2017","journal-title":"Blood"},{"issue":"5","key":"2026102711120399900_bib21","doi-asserted-by":"crossref","first-page":"874","DOI":"10.3324\/haematol.2017.182907","article-title":"Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysis","volume":"103","author":"Mato","year":"2018","journal-title":"Haematologica"},{"issue":"12","key":"2026102711120399900_bib22","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1182\/blood-2018-11-846808","article-title":"How I manage ibrutinib intolerance and complications in patients with chronic lymphocytic leukemia","volume":"133","author":"Stephens","year":"2019","journal-title":"Blood"},{"key":"2026102711120399900_bib23","doi-asserted-by":"crossref","first-page":"919","DOI":"10.2147\/DDDT.S250823","article-title":"Zanubrutinib (BGB-3111), a second-generation selective covalent inhibitor of Bruton\u2019s tyrosine kinase and its utility in treating chronic lymphocytic leukemia","volume":"15","author":"Rhodes","year":"2021","journal-title":"Drug Des Devel Ther"},{"issue":"23","key":"2026102711120399900_bib24","doi-asserted-by":"crossref","first-page":"6323","DOI":"10.1158\/1078-0432.CCR-21-1704","article-title":"The MAGNOLIA trial: zanubrutinib, a next-generation Bruton tyrosine kinase inhibitor, demonstrates safety and efficacy in relapsed\/refractory marginal zone lymphoma","volume":"27","author":"Opat","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"2","key":"2026102711120399900_bib25","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1111\/bjh.12011","article-title":"Risk stratification for splenic marginal zone lymphoma based on haemoglobin concentration, platelet count, high lactate dehydrogenase level and extrahilar lymphadenopathy: development and validation on 593 cases","volume":"159","author":"Montalb\u00e1n","year":"2012","journal-title":"Br J Haematol"},{"issue":"12","key":"2026102711120399900_bib26","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1182\/blood-2017-03-771915","article-title":"A MALT lymphoma prognostic index","volume":"130","author":"Thieblemont","year":"2017","journal-title":"Blood"},{"issue":"27","key":"2026102711120399900_bib27","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J Clin Oncol"},{"issue":"4","key":"2026102711120399900_bib28","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1200\/JCO.1999.17.4.1244","article-title":"Report of an international workshop to standardize response criteria for non-Hodgkin\u2019s lymphomas. NCI Sponsored International Working Group","volume":"17","author":"Cheson","year":"1999","journal-title":"J Clin Oncol"},{"issue":"11","key":"2026102711120399900_bib29","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1182\/blood.2020010263","article-title":"Validation of POD24 as a robust early clinical end point of poor survival in FL from 5225 patients on 13 clinical trials","volume":"139","author":"Casulo","year":"2022","journal-title":"Blood"},{"issue":"5","key":"2026102711120399900_bib30","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1097\/PAS.0000000000000411","article-title":"MYD88 (L265P) somatic mutation in marginal zone B-cell lymphoma","volume":"39","author":"Martinez-Lopez","year":"2015","journal-title":"Am J Surg Pathol"},{"issue":"14","key":"2026102711120399900_bib31","doi-asserted-by":"crossref","first-page":"3531","DOI":"10.1182\/bloodadvances.2022009412","article-title":"Molecular associations of response to the new-generation BTK inhibitor zanubrutinib in marginal zone lymphoma","volume":"7","author":"Tatarczuch","year":"2023","journal-title":"Blood Adv"},{"issue":"22","key":"2026102711120399900_bib32","doi-asserted-by":"crossref","first-page":"6801","DOI":"10.1182\/bloodadvances.2023010668","article-title":"Safety and efficacy of zanubrutinib in relapsed\/refractory marginal zone lymphoma: final analysis of the MAGNOLIA study","volume":"7","author":"Opat","year":"2023","journal-title":"Blood Adv"},{"issue":"22","key":"2026102711120399900_bib33","doi-asserted-by":"crossref","first-page":"5773","DOI":"10.1182\/bloodadvances.2020003121","article-title":"Durable ibrutinib responses in relapsed\/refractory marginal zone lymphoma: long-term follow-up and biomarker analysis","volume":"4","author":"Noy","year":"2020","journal-title":"Blood Adv"},{"issue":"2","key":"2026102711120399900_bib34","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1080\/10428194.2024.2416577","article-title":"Matching-adjusted indirect comparisons of zanubrutinib (MAGNOLIA, BGB-3111-AU-003) versus ibrutinib (PCYC-1121) and rituximab (CHRONOS-3) in relapsed\/refractory marginal zone lymphoma","volume":"66","author":"Thieblemont","year":"2025","journal-title":"Leuk Lymphoma"},{"issue":"11","key":"2026102711120399900_bib35","doi-asserted-by":"crossref","first-page":"3472","DOI":"10.1182\/bloodadvances.2021006083","article-title":"Zanubrutinib monotherapy in relapsed\/refractory indolent non-Hodgkin lymphoma","volume":"6","author":"Phillips","year":"2022","journal-title":"Blood Adv"},{"issue":"1","key":"2026102711120399900_bib36","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1111\/bjh.18368","article-title":"A phase 2, multicentre, open-label trial (ACE-LY-003) of acalabrutinib in patients with relapsed or refractory marginal zone lymphoma","volume":"199","author":"Strati","year":"2022","journal-title":"Br J Haematol"},{"issue":"suppl 1","key":"2026102711120399900_bib37","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1182\/blood-2023-182347","article-title":"Efficacy and safety of ibrutinib in relapsed or refractory marginal zone lymphomas: the \u201cReal World\u201d Italian experience","volume":"142","author":"Merli","year":"2023","journal-title":"Blood"},{"issue":"1","key":"2026102711120399900_bib38","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1186\/s13045-022-01316-1","article-title":"Predictive factors and outcomes for ibrutinib in relapsed\/refractory marginal zone lymphoma: a multicenter cohort study","volume":"15","author":"Epperla","year":"2022","journal-title":"J Hematol Oncol"},{"issue":"9","key":"2026102711120399900_bib39","doi-asserted-by":"crossref","first-page":"2166","DOI":"10.1111\/bcp.16127","article-title":"Cardiovascular events of Bruton\u2019s tyrosine kinase inhibitors: a real-world study based on the United States Food and Drug Administration adverse event reporting system database","volume":"90","author":"Zhao","year":"2024","journal-title":"Br J Clin Pharmacol"},{"issue":"4","key":"2026102711120399900_bib40","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1182\/bloodadvances.2021005621","article-title":"Pooled safety analysis of zanubrutinib monotherapy in patients with B-cell malignancies","volume":"6","author":"Tam","year":"2022","journal-title":"Blood Adv"},{"issue":"1","key":"2026102711120399900_bib41","doi-asserted-by":"crossref","first-page":"e35","DOI":"10.1016\/S2352-3026(22)00320-9","article-title":"Zanubrutinib in patients with previously treated B-cell malignancies intolerant of previous Bruton tyrosine kinase inhibitors in the USA: a phase 2, open-label, single-arm study","volume":"10","author":"Shadman","year":"2023","journal-title":"Lancet Haematol"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/20\/7036\/2595305\/blooda_adv-2026-020480-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/20\/7036\/2595305\/blooda_adv-2026-020480-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T15:12:14Z","timestamp":1793113934000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/10\/20\/7036\/570523\/Real-world-effectiveness-and-safety-of"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,16]]},"references-count":41,"journal-issue":{"issue":"20","published-print":{"date-parts":[[2026,10,27]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2026020480","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,10,27]]},"published":{"date-parts":[[2026,10,16]]}}}